At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 385 enrolled
Drug / intervention
AZD9056 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine
In Brief
A Phase 2 clinical trial evaluating AZD9056, Etanercept, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 385 participants across 51 sites in 12 countries.
Detailed Summary
The purpose of this study is to confirm that AZD9056 is effective in treating rheumatoid arthritis with regard to signs and symptoms and to determine what dose is favourable over a 6-month treatment period. Patients will receive background treatment with either Methotrexate or Sulphasalazine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Australia, Belgium, Canada, Czechia, France, Mexico, Poland, Romania, Russia, Slovakia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Study CompletionMar 2009
TodayJul 2026
First PostedAug 24, 2007
Enrollment StartAug 1, 2007
Study CompletionMar 1, 2009
TodayJul 2, 2026
Posted 18.9 years ago
Interventions
AZD9056drug
Etanerceptdrug
Placebodrug